Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b, Dose-escalating Safety and Immunogenicity Trial of the Novel Monovalent Ebola Zaire Candidate Vaccine, cAd3-EBO Z and the Heterologous Prime-boost Candidate Vaccine Regimen of cAD3-EBO Z Followed by MVA-BN® Filo in Malian Adults Aged 18-50 Years.

NCT02267109 is registered in ClinicalTrials.gov with University of Maryland, Baltimore as lead sponsor.

NCT NCT02267109
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02267109 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b, Dose-escalating Safety and Immunogenicity Trial of the Novel Monovalent Ebola Zaire Candidate Vaccine, cAd3-EBO Z and the Heterologous Prime-boost Candidate Vaccine Regimen of cAD3-EBO Z Followed by MVA-BN® Filo in Malian Adults Aged 18-50 Years.
Lead sponsor
University of Maryland, Baltimore
Phase
Phase 1
Overall status
Completed
Start date
October 31, 2014
Completion date
April 20, 2016
Enrollment
91 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

ebola virus disease, hemorrhagic fever